Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition).
作者信息
Liang Wenhua, Cai Kaican, Chen Chun, Chen Haiquan, Fang Wentao, Fu Junke, Fu Xiangning, Gao Shugeng, Hu Jian, Huang Yunchao, Jiang Ganning, Jiao Wenjie, Li Shanqing, Li Gaofeng, Li Hecheng, Li Hui, Li Xiaofei, Liang Naixin, Liu Deruo, Liu Hongxu, Liu Jun, Liu Lunxu, Liu Yang, Luo Qingquan, Ma Haitao, Mao Weimin, Peng Zhongmin, Qiao Guibin, Shao Guoguang, Tan Lijie, Tan Qunyou, Wang Qun, Wang Changli, Wu Qingchen, Xu Shidong, Xu Songtao, Xu Lin, Yang Yue, Yu Fenglei, Zhang Baijiang, Zhang Lanjun, Zhao Bo, Zhi Xiuyi, Brunelli Alessandro, Petersen René Horsleben, Liu Chia-Chuan, Ricciuti Biagio, Metro Giulio, Tuzi Alessandro, Suter Matteo B, Evison Matthew, Seki Nobuhiko, Sasada Shinji, Izumo Takhiro, Cho William Chi-Shing, He Jianxing
机构信息
Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.
Guangzhou Institute of Respiratory Disease, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou 510120, China.
出版信息
Transl Lung Cancer Res. 2019 Dec;8(6):1163-1173. doi: 10.21037/tlcr.2019.12.14.
Abstract
摘要
相似文献
1
Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition).转化医学学会关于表皮生长因子受体（EGFR）突变型肺癌术后管理的共识（2019年版）
Transl Lung Cancer Res. 2019 Dec;8(6):1163-1173. doi: 10.21037/tlcr.2019.12.14.
2
Society for Translational Medicine consensus (2019 edition) shows an option for postoperative management of EGFR-mutant lung cancer.转化医学学会共识（2019年版）展示了表皮生长因子受体（EGFR）突变型肺癌术后管理的一种选择。
J Thorac Dis. 2020 Aug;12(8):4561-4563. doi: 10.21037/jtd.2020.04.34.
3
Erratum to Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition).《转化医学学会关于EGFR突变型肺癌术后管理的共识（2019年版）》勘误
Transl Lung Cancer Res. 2020 Jun;9(3):944. doi: 10.21037/tlcr.2020.03.39.
4
One step too far in the right direction: The Society for Translational Medicine 2019 consensus on postoperative management of EGFR-mutant lung cancer.在正确方向上迈出的一小步：转化医学学会2019年关于表皮生长因子受体突变型肺癌术后管理的共识
J Thorac Dis. 2020 Sep;12(9):5046-5049. doi: 10.21037/jtd-2020-51.
5
The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016.国际肺癌研究协会关于优化 EGFR 突变阳性非小细胞肺癌管理的共识声明：2016 年现状。
J Thorac Oncol. 2016 Jul;11(7):946-63. doi: 10.1016/j.jtho.2016.05.008. Epub 2016 May 23.
6
Correlation of EGFR mutation status with predominant histologic subtype of adenocarcinoma according to the new lung adenocarcinoma classification of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society.根据国际肺癌研究协会/美国胸科学会/欧洲呼吸学会新的肺腺癌分类，EGFR突变状态与腺癌主要组织学亚型的相关性。
Arch Pathol Lab Med. 2014 Oct;138(10):1353-7. doi: 10.5858/arpa.2013-0376-OA. Epub 2014 Feb 26.
7
Should EGFR mutations be tested in advanced lung squamous cell carcinomas to guide frontline treatment?在晚期肺鳞状细胞癌中是否应该检测表皮生长因子受体（EGFR）突变以指导一线治疗？
Cancer Chemother Pharmacol. 2014 Oct;74(4):661-5. doi: 10.1007/s00280-014-2536-3. Epub 2014 Jul 23.
8
Practice guidelines for management of ovarian cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement.韩国妇科肿瘤学会卵巢癌管理实践指南：韩国共识声明。
J Gynecol Oncol. 2018 Jul;29(4):e56. doi: 10.3802/jgo.2018.29.e56. Epub 2018 Mar 10.
9
Cetuximab-modified mesoporous silica nano-medicine specifically targets EGFR-mutant lung cancer and overcomes drug resistance.西妥昔单抗修饰的介孔二氧化硅纳米药物特异性靶向表皮生长因子受体（EGFR）突变的肺癌并克服耐药性。
Sci Rep. 2016 May 6;6:25468. doi: 10.1038/srep25468.
10
Increased Synthesis of MCL-1 Protein Underlies Initial Survival of -Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target.MCL-1 蛋白的过度合成是导致 - 突变型肺癌对 EGFR 抑制剂最初产生耐药性的原因，并为新的药物靶点提供了依据。
Clin Cancer Res. 2018 Nov 15;24(22):5658-5672. doi: 10.1158/1078-0432.CCR-18-0304. Epub 2018 Aug 7.
引用本文的文献
1
Consensus clustering based on CT radiomics has potential for risk stratification of patients with clinical T1 stage lung adenocarcinoma.基于CT影像组学的一致性聚类在临床T1期肺腺癌患者的风险分层中具有潜力。
BMC Med Imaging. 2025 Jul 1;25(1):231. doi: 10.1186/s12880-025-01795-x.
2
Pharmacokinetics, tissue distribution, and antitumor activity of a novel compound, NY-2, in non-small cell lung cancer.新型化合物NY-2在非小细胞肺癌中的药代动力学、组织分布及抗肿瘤活性
Front Pharmacol. 2023 Jan 16;13:1074576. doi: 10.3389/fphar.2022.1074576. eCollection 2022.
3
Machine learning and BP neural network revealed abnormal B cell infiltration predicts the survival of lung cancer patients.机器学习和BP神经网络显示，异常B细胞浸润可预测肺癌患者的生存率。
Front Oncol. 2022 Oct 11;12:882018. doi: 10.3389/fonc.2022.882018. eCollection 2022.
4
[A Review on Pathological High-risk Factors and Postoperative Adjuvant Chemotherapy in Stage IA Lung Adenocarcinoma].[ⅠA期肺腺癌的病理高危因素及术后辅助化疗综述]
Zhongguo Fei Ai Za Zhi. 2022 Aug 20;25(8):593-600. doi: 10.3779/j.issn.1009-3419.2022.101.30.
5
Postoperative adjuvant EGFR-TKIs for resected -mutant NSCLC-opportunities and obstacles.用于可切除的EGFR突变型非小细胞肺癌的术后辅助表皮生长因子受体酪氨酸激酶抑制剂——机遇与障碍
Ann Transl Med. 2021 Apr;9(7):586. doi: 10.21037/atm-2020-133.
6
EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong - A cost-effectiveness analysis.在香港，使用埃克替尼、厄洛替尼和吉非替尼进行表皮生长因子受体突变指导的晚期非小细胞肺癌的成本效益分析。
PLoS One. 2021 Mar 1;16(3):e0247860. doi: 10.1371/journal.pone.0247860. eCollection 2021.
7
Endothelial growth factor receptor-mutant lung cancer and post-operative care management: one size does not fit all.内皮生长因子受体突变型肺癌与术后护理管理：一刀切并不适用。
Ann Transl Med. 2020 Dec;8(24):1697. doi: 10.21037/atm-20-4408.
8
Optimizing adjuvant therapy in -mutated non-small cell lung cancer.优化KRAS突变型非小细胞肺癌的辅助治疗
Ann Transl Med. 2020 Dec;8(23):1613. doi: 10.21037/atm-20-3982.
9
Different perspectives and viewpoints on the postoperative management of EGFR-mutant lung cancer.关于表皮生长因子受体（EGFR）突变型肺癌术后管理的不同观点和看法。
Ann Transl Med. 2020 Sep;8(18):1201. doi: 10.21037/atm.2020.04.34.
10
Adjuvant treatment with EGFR TKI in resected non-small cell lung cancer with EGFR mutation: all that glitters is not gold!表皮生长因子受体酪氨酸激酶抑制剂用于切除的表皮生长因子受体突变非小细胞肺癌的辅助治疗：闪光的未必都是金子！
Ann Transl Med. 2020 Sep;8(18):1199. doi: 10.21037/atm.2020.04.57.
本文引用的文献
1
A comparison of mutation status in tissue and plasma cell-free DNA detected by ADx-ARMS in advanced lung adenocarcinoma patients.ADx-ARMS检测晚期肺腺癌患者组织和血浆游离DNA中突变状态的比较。
Transl Lung Cancer Res. 2019 Apr;8(2):135-143. doi: 10.21037/tlcr.2019.03.10.
2
The impact of epidermal growth factor receptor mutations on the prognosis of resected non-small cell lung cancer: a meta-analysis of literatures.表皮生长因子受体突变对手术切除的非小细胞肺癌预后的影响：文献的荟萃分析
Transl Lung Cancer Res. 2019 Apr;8(2):124-134. doi: 10.21037/tlcr.2019.03.14.
3
Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database.基于临床基因组数据库的非小细胞肺癌患者的患者特征和肿瘤基因组与临床结局的相关性分析。
JAMA. 2019 Apr 9;321(14):1391-1399. doi: 10.1001/jama.2019.3241.
4
Adjuvant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (TKIs) in Resected Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-analysis.辅助表皮生长因子受体酪氨酸激酶抑制剂（TKIs）在非小细胞肺癌（NSCLC）中的应用：一项系统评价和荟萃分析。
Am J Clin Oncol. 2019 May;42(5):440-445. doi: 10.1097/COC.0000000000000533.
5
A Nomogram for Predicting Cancer-Specific Survival of TNM 8th Edition Stage I Non-small-cell Lung Cancer.第八版 TNM 分期Ⅰ期非小细胞肺癌患者癌症特异性生存的列线图预测模型。
Ann Surg Oncol. 2019 Jul;26(7):2053-2062. doi: 10.1245/s10434-019-07318-7. Epub 2019 Mar 21.
6
Mutation Profile of Resected -Mutated Lung Adenocarcinoma by Next-Generation Sequencing.下一代测序技术检测切除的 - 突变型肺腺癌的突变谱。
Oncologist. 2019 Oct;24(10):1368-1374. doi: 10.1634/theoncologist.2018-0567. Epub 2019 Mar 14.
7
SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.选择：表皮生长因子受体突变型非小细胞肺癌患者术后辅助厄洛替尼的 II 期临床试验。
J Clin Oncol. 2019 Jan 10;37(2):97-104. doi: 10.1200/JCO.18.00131. Epub 2018 Nov 16.
8
Gefitinib Versus Adjuvant Chemotherapy in Patients With Stage II-IIIA Non-Small-Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center Retrospective Study.表皮生长因子受体突变阳性的 II-IIIA 期非小细胞肺癌患者中吉非替尼对比辅助化疗的疗效：一项单中心回顾性研究。
Clin Lung Cancer. 2018 Nov;19(6):484-492. doi: 10.1016/j.cllc.2018.05.007. Epub 2018 May 26.
9
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018：GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
10
Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.厄洛替尼对比长春瑞滨联合顺铂用于表皮生长因子受体突变阳性的 IIIA 期非小细胞肺癌中国患者的辅助治疗（EVAN）：一项随机、开放标签、二期临床试验。
Lancet Respir Med. 2018 Nov;6(11):863-873. doi: 10.1016/S2213-2600(18)30277-7. Epub 2018 Aug 24.
Zotero 插件